Targeting the 5′ untranslated region of SMN2 as a therapeutic strategy for spinal muscular atrophy
Open Access
- 1 March 2021
- journal article
- research article
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 23, 731-742
Abstract
No abstract availableKeywords
Funding Information
- Wellcome Trust
- Medical Research Council
- National Institute of Neurological Disorders and Stroke
This publication has 65 references indexed in Scilit:
- Conditional deletion of SMN in cell culture identifies functional SMN allelesHuman Molecular Genetics, 2020
- Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular AtrophyNew England Journal of Medicine, 2017
- Antisense Oligonucleotides: Translation from Mouse Models to Human Neurodegenerative DiseasesNeuron, 2017
- Design of Potent mRNA Decapping Scavenger Enzyme (DcpS) Inhibitors with Improved Physicochemical Properties To Investigate the Mechanism of Therapeutic Benefit in Spinal Muscular Atrophy (SMA)Journal of Medicinal Chemistry, 2017
- Small antisense oligonucleotides against G-quadruplexes: specific mRNA translational switchesNucleic Acids Research, 2014
- The DcpS inhibitor RG3039 improves motor function in SMA miceHuman Molecular Genetics, 2013
- p53 induces transcriptional and translational programs to suppress cell proliferation and growthGenome Biology, 2013
- Antisense Masking of an hnRNP A1/A2 Intronic Splicing Silencer Corrects SMN2 Splicing in Transgenic MiceThe American Journal of Human Genetics, 2008
- Essential Role for the SMN Complex in the Specificity of snRNP AssemblyScience, 2002
- The Neurobiology of Childhood Spinal Muscular AtrophyNeurobiology of Disease, 1996